Appendix
← Clinical Reader
Infectious Disease

Etesevimab

As of January 24, 2022, the United States Food and Drug Associated (FDA) fact sheet for the drug etesevimab states that "due to the high frequency of the Omicron variant, bamlanivimab and etesevimab, administered together, are not currently authorized for use in any U.S. region because of markedly reduced activity against the Omicron variant. These drugs may not be administered for treatment or post-exposure prevention of COVID-19 under the Emergency Use Authorization until further notice by the

v1 · Reviewed Nov 7, 2026 by Automated Clinical Reviewer (Strict Verbatim v1)
  • As of January 24, 2022, the United States Food and Drug Associated (FDA) fact sheet for the drug etesevimab states that "due to the high frequency of the Omicron variant, bamlanivimab and etesevimab, administered together, are not currently authorized for use in any U.S. region because of markedly reduced activity against the Omicron variant.
  • This topic is for historical purposes only to review this therapy's indications, mechanism, and administration when it was first developed.
  • The combination product (etesevimab and bamlanivimab) is not authorized for hospitalized patients with SARS-CoV-2 or those patients requiring oxygen therapy.
  • The combination product (bamlanivimab and etesevimab) must be given immediately after a positive test result and within 10 days of symptom onset.
  • The FDA (Food and Drug Administration) has approved both combination products through EUA (Emergency Use Authorizations), which can be used for mild to moderate SARS-CoV-2 in non-hospitalized patients at high risk for progressing to severe disease.
  • The combination product (etesevimab and bamlanivimab) can be used in adults and pediatrics if they are at least 12 years of age and weigh 40 kg or more with mild to moderate SARS CoV-2.
  • The patients are considered at high risk of progressing to severe COVID-19 or hospitalization if they satisfy 1 of the criteria below:
  • Body mass index 35 and above
  • Age above 65 years
  • Chronic Renal disease
  • Pregnancy
  • Diabetes Mellitus
bamlanivimab and etesevimab
infusion
Adult
700 mg of bamlanivimab and 1400 mg of etesevimab
Renal
Not specified in source
Duration
Not specified in source
  • There are no strict contraindications to using etesevimab.
  • Pregnant patients : Etesevimab and bamlanivimab can only be prescribed for pregnant patients with SARS-CoV-2 only if the benefit overbalances the risk for the duo (fetus and mother).
  • Lactating mother : No data has shown any potential adverse effects on the breastfed child.
  • Pediatric patients : Etesevimab and bamlanivimab are not recommended for children less than 12 years or children weighing < 40 Kg.
  • Geriatric patients : The pharmacokinetics of etesevimab and bamlanivimab in elderly patients are similar to those of young adults, so no dose adjustment is required.
  • Hepatic and Renal Impairment : The dose adjustment is not required for renal and mild hepatic impairment.
  • Anaphylaxis or severe hypersensitivity reactions can be possible with bamlanivimab monotherapy or combination therapy.
  • If an infusion-related reaction is suspected, consider slowing or stopping the infusion.
  • Etesevimab and bamlanivimab infusions should be given only by a qualified healthcare professional in an outpatient facility who can manage hypersensitive reactions.
  • The patient should be monitored for anaphylaxis for at least 1 hour after infusion completion.
  • If an overdose of bamlanivimab and etesevimab happens, treatment comprises supportive measures, including vitals and clinical status monitoring.
  • The healthcare team comprising the physician, nurse practitioner, and nurse is jointly responsible for reporting medication errors and serious adverse events related to etesevimab and bamlanivimab treatment within 7 days from the onset of the event.
  • review
    Etesevimab. StatPearls [Internet] — Palanikumar Balasundaram, Toshiba Morgan-Joseph — StatPearls Publishing, 2023

Decision support only. Verify against local protocols and current labeling. Source: www.ncbi.nlm.nih.gov